NCT05196971View on ClinicalTrials.gov

A Study To Evaluate The Safety, Tolerability And Pharmacokinetics of HS-10345 In Treatment-Resistant Depression

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 28, 2021

Primary Completion Date

April 30, 2022

Study Completion Date

October 31, 2022

Conditions
Treatment Resistant Depressive Disorder
Interventions
DRUG

HS-10345 84mg

6 sprays of HS-10345 84 mg self-administered as an intranasal formulation for 4 days (Days 1, 4, 8, 11) during the double-blind phase

DRUG

Placebo

6 sprays of placebo self-administered as an intranasal formulation for 4 days (Days 1, 4, 8, 11) during the double-blind phase

Trial Locations (1)

Unknown

Beijing Anding Hospital, Capital Medical University, Beijing

Sponsors
All Listed Sponsors
lead

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY

NCT05196971 - A Study To Evaluate The Safety, Tolerability And Pharmacokinetics of HS-10345 In Treatment-Resistant Depression | Biotech Hunter | Biotech Hunter